Although antigen loss variants, major histocompatibility ( MHC ) class I down -regulation, or the expression of inhibitory molecules may explain the failure of immunosurveillance against some tumors, this seems not to apply for many other solid peripheral or lymphohematopoietic tumors. Why then is immunosurveillance so ineffective and can it be improved? This review focuses on one important aspect of tumor immunity, namely the relevance of antigen dose and localization. Immune responses in vivo are induced in organized lymphoid tissues, i.e., in lymph nodes and spleen. The antigen dose that reaches secondary lymphoid organs over time is a crucial parameter that drives antiviral and antitumoral immune responses. Tumors use various strategies to prevent efficient presentation of their antigens in lymphoid organs. A major obstacle to the induction of an endogenous tumor -specific cytotoxic T lymphocyte ( CTL ) response is the inefficient presentation of tumor antigen on MHC class I molecules of professional antigenpresenting cells. Peripheral solid tumors that develop outside lymphoid organs are, therefore, often ignored by the immune system. In other situations, tumors -especially of lymphohematopoietic origin -may tolerize specific CTLs. Understanding tumor immunosurveillance is key to the design of efficient antitumor vaccines. Attempts to improve immunity to tumors include vaccination strategies to ( a ) provide the tumor antigen to secondary lymphoid organs using recombinant viruses or dendritic cells as carriers, ( b ) express costimulatory signals on tumor cells, or ( c ) improve the efficiency of cross -priming.
I
nfectious pathogens may predominantly infect immunoincompetent young individuals and, therefore, endanger the species. The immune system coevolved with infectious diseases in a way that allows survival of the host and the pathogen. In contrast, because carcinomas and sarcomas usually arise in individuals beyond reproductive age, these tumors are more a problem for the individual patient than for the population as a whole. Thus, the immune system did not develop special strategies to protect against cancer; instead, tumors are fought by an immune system that has been shaped by infectious pathogens. Indeed, the immunobiology of cancer and infectious diseases may be overlapping, e.g., the recognition and elimination of both virus -infected and tumor cells seem to depend on similar mechanisms. The general means by which the immune system reacts against viruses and cancer are, therefore, discussed together in this review.
The immunological effector mechanisms necessary for the efficient control of a bacterial or viral infection are dependent upon the specific route of entry used by the infectious agent. A hematogenously spreading infectious pathogen is best controlled by neutralizing antibodies. 1 The protection of vital target organs by IgM and IgG antibodies is illustrated by infections with Streptococcus pneumoniae, Haemophilus influenzae, enteroviridae, measles, influenza, and poxvirus. 2, 3 In contrast, infections of peripheral solid organs with noncytopathic viruses such as hepatitis B and C virus in humans or lymphocytic choriomeningitis virus ( LCMV ) in mice are largely controlled by activated cytotoxic T lymphocytes (CTLs ), which have the capacity to extravasate and enter the infected peripheral solid tissue; antibodies play virtually no role in this process. 4 Solid tumors, including carcinomas and sarcomas, often express a cell -associated tumor antigen 5, 6 and, therefore, resemble viral infections of peripheral tissues in many ways. Similar to protection against noncytopathic viruses, the main effector mechanism of adaptive immunity to control peripheral tumors may be CTL, and antibodies seem to play only a limited role. Therefore, this review tries to define principles by which a tumor-or virus -specific CTL response is elicited and summarizes vaccination strategies being used to improve immunity to tumors.
Immunosurveillance of tumors
In the 1950s, the immunosurveillance hypothesis was formulated. 7, 8 It described that the immune system of the host recognizes antigens of newly arising tumors and eliminates these tumors before they become clinically evident. Progressive cancer was seen as a rare event in which the tumor cell escaped the efficient control of the immune system. Today, it is quite clear that the immune system does not play this central role in the control of early tumor development. 9, 10 However, the contribution of the host immune response and the relevance of B and T cells in tumor control are still poorly understood.
Role of cytotoxic T cells
Clinically manifest tumors have obviously not been controlled efficiently by immunity. Many tumors apparently use various strategies to evade the recognition by CTL. Mechanisms such as major histocompatibility (MHC ) class I down -regulation, antigen loss, antigen modulation, or the expression of inhibitory molecules may explain the failure of an endogenous immune response in tumor control. 11 -15 Nevertheless, various antigenic tumors, e.g., melanomas, renal cancers, or breast tumors, may successfully grow in an immunocompetent host. Tumor-infiltrating lymphocytes ( TILs ) have been found in many experimental models and have been isolated from human tumors. 16, 17 Their existence indicates that although an immune response was induced, it was insufficient to control or reject the tumor completely. However, other observations may suggest that the immunosurveillance of tumors may be of importance and sometimes is very efficient. For example, immunosuppression leads to a higher incidence of virally triggered tumors or tumors of lymphohematopoietic or vascular origin, but interestingly does not influence the incidence of the more common tumors such as breast cancer, colon cancer, or lung cancer. 18 -20 Evidence supporting only a limited role of the host's immune response against tumors was derived from observations that nude mice with impaired T-and Bcell development have a normal incidence of spontaneously arising tumors. 21 However, nude mice are not completely deficient in B and T cells as they possess some limited residual T-and B-cell function. More recent experiments in mice deficient in either RAG genes ( thus lacking T and B cells) or STAT1 genes (thus lacking interferon -mediated pathways ) revealed a higher incidence of spontaneous tumors. 22 However, even RAG /STAT1 double knockout mice that lack important effector mechanisms of both adaptive and innate immunity developed tumors only late and the tumor incidence during the first year was comparable to controls, indicating an only limited efficiency of the endogenous immune response in controlling tumorigenesis. A higher incidence of chemically induced tumors in perforin -deficient mice indicates that the perforin pathway and probably CD8 + T cells may play a role in tumor immunosurveillance; 23 however, only the incidence of spontaneous lymphohematopoietic but not solid tumors is increased in these mice. 24 Together, these observations suggest that the host immune response may, in some situations, control tumors, but in others, especially against peripheral solid tumors, the endogenous immune response is often not an effective barrier for tumor growth.
Role of antibodies
In the course of most CTL -mediated immune responses, including antitumor immune responses, specific antibodies are also produced. In the last few years, the relative efficacy of antitumor antibodies for the treatment of certain breast cancers or B -cell lymphomas 25 renewed the interest of immunologists in humoral antitumor responses. Antibodies are not toxic for a virus -infected cell or a tumor cell per se but act either by blocking vital signaling molecules on the cell surface or by a secondary effector mechanism including antibody -dependent cellular cytotoxicity (ADCC ) or complement -dependent cytotoxicity (CDC ). 26 In mice, antimelanoma antibodies inhibit tumor growth in a FcgR -dependent manner. 27 In addition, the importance of the Fc -FcgR interaction for antitumor activity was shown for the clinically important antibodies transtuzumab ( Herceptin) and rituximab ( Mabtera, Rituxan ) as well as for intracerebral therapy with an anti -EGF receptor antibody in a brain tumor model. 28, 29 The antitumor effect of Herceptin and Rituxan was greatly reduced in mice that lack the activation receptors FcgRI and FcgRIII, whereas disruption of the gene that encodes for the inhibitory receptor FcgRIIB substantially enhanced antitumor activity. In contrast, evidence of a relevance of CDC is currently limited to in vitro experiments. Antibodies with improved ability to bind to the complement component C1q have been created using site-directed mutagenesis. 30 These antibodies mediated an enhanced CDC against target cells in vitro, but the relevance of CDC for the protection against tumors in vivo remains to be shown. Although ADCC seems to be an important effector mechanism of passively transferred monoclonal antibody, the physiological relevance of an endogenous antibody response to tumor antigens seems to be limited to very few experimental systems.
An interesting possibility is that antibodies influence the induction of cytotoxic T cells. The data on this topic are controversial. Antibodies have been shown to enhance cross -presentation of tumor antigens. Targeting antigen to FcgR promoted cross -presentation by several orders of magnitude in mouse bone marrow -derived dendritic cells ( DCs ) 31, 32 and recent in vitro experiments suggested a role for antitumor antibodies in the induction of antitumor CTLs. Coating of myeloma cells with antisyndecan antibodies increased cross -presentation and cross -priming of the tumor antigens NY-ESO1 and MAGE3. 33 It is important to note here that the cross -priming of all these antigens was studied in vitro. In a mouse model, CD8 + T-cell depletion prevented treatment of established solid tumors with antitumor mAbs, suggesting a role of antibodies in the induction of CTLs in vivo. 34 In contrast, a study in B cell -deficient mice revealed that the induction of an antitumor response in the absence of B cells and antibodies is enhanced. 35 It was speculated that antigen -presenting cells ( APCs ), such as B cells, macrophages, and DCs, compete for antigen. Taken together, antibodies may enhance or impair the induction of tumorspecific CTLs in different ways. The requirements for either of these processes and especially their relevance for the protection against tumors in vivo remain to be analyzed in clearly defined model situations.
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Induction of T cells

Antigen dose and localization
Lymphocytes, macrophages, and APCs perform their effector functions as single cells, but in order to activate naive CTL, they need to interact and collaborate in organized lymphoid tissue. 36 -39 The term organized lymphoid tissue defines structures such as follicles, marginal zone, germinal center, periarteriolar sheath, and red pulp. These anatomical structures determine the localization of antigen, cytokines, and bystander contacts through costimulatory molecules. Therefore, lymph nodes and the spleen provide the milieu necessary for lymphoid cell interactions and activation.
The localization and the amount of viral or tumor antigen that reaches secondary lymphoid organs over time are, therefore, crucial parameters for the induction of CTLs; 40 -43 antigens that never reach organized lymphoid tissues in a sufficient amount are ignored by the immune system. 44, 45 Several viruses avoid immunosurveillance simply by staying outside of lymphoid tissues. A classic example is Papilloma virus that infects basal layers of epidermal cells and replicates only in keratinocytes without infecting Langerhans' cells. 46 Experimental evidence for the necessity of antigen reaching secondary lymphoid organs for the induction of a CTL response came from very early experiments. In 1957, Frey and Wenk 47 showed that the sensitization of isolated skin flaps of guinea pigs is dependent on an intact draining lymph node and lymph vessel. Supporting evidence for the importance of the antigen localization was provided by experiments performed by Lafferty and Woolnough. 48 They succeeded in transplanting allogeneic thyroid epithelial cells after depletion of passenger leukocytes under the kidney capsule. The graft did not induce an immune response but also did not tolerize the host immune system. Diabetes models with a transgenic antigen expressed on islet cells are very informative for the role of the antigen localization in the induction of CTL. 44, 49 RIP-GP transgenic mice express the glycoprotein (GP ) of LCMV under the ratinsulin promoter ( RIP ). These RIP -GP mice do not spontaneously develop diabetes. In contrast, if these mice are infected with replicating LCMV virus or immunized with DCs expressing LCMV-GP, they mount an LCMV-GPspecific CTL response and develop diabetes. 44, 49, 50 These experiments illustrate that T cells specific for LCMV-GP are present, but because the antigen is expressed strictly outside secondary lymphoid organs and the antigen does not reach local lymph nodes in a sufficient quantity over a sufficient time period, no specific CTLs are induced and the peripheral antigen is ignored. Alymphoplastic mice (aly /aly ) lack lymph nodes but possess a spleen with functionally normal CTL. 41, 51 Although aly /aly mice generated detectable, but reduced, CTL responses after infection with vaccinia virus and LCMV, the elimination of these viruses was either delayed or virtually impossible; irrespective of the dose or the route of infection, aly /aly mice developed life -long LCMV persistence and splenectomized aly / aly mice did not mount a CTL response at all after infection with LCMV. 41 More recently, it was shown that aly /aly mice are immunologically ignorant of a cardiac allograft. 52 These results document the critical role of secondary lymphoid organs in the induction of naive T cells. How may these results from experiments in autoimmunity and viral immunity models be translated to tumor immunity? Solid tumors arise from a single cell in the periphery (i.e., outside secondary lymphoid organs) and early in the development of the tumor, no or only few antigenexpressing tumor cells will reach secondary lymphoid organs. We recently showed for a lymphoma, sarcoma, carcinoma, and melanoma -each expressing the same model tumor antigen (LCMV-GP ) -that the migration of the tumor cells to secondary lymphoid organs is crucial for the induction of an immune response. 42, 53 Tumors regularly grew without inducing an LCMV-GP -specific CTL response if they were transplanted as solid tumor fragments. These antigenic peripheral solid tumors stayed strictly outside lymphoid organs and no tumor cells could be detected in local lymph nodes ( Fig 1A ) . In contrast, if the same cells were injected as single cell suspension subcutaneously ( s.c. ), they reached local lymph nodes and, as a consequence, a specific CTL response was induced ( Fig 1C ) . In aly /aly mice, tumor cells cannot reach local lymph nodes because they are absent. Therefore, in these mice, s.c. injected tumor cells in suspension did not induce a CTL response and tumors grew. In addition, the direct injection of the tumor cells into secondary lymphoid organs is 100-1000 times more efficient in the induction of a tumor-specific immune response than a s.c. injection. 40 Peripheral solid tumors also did not tolerize the immune system because immunization with replicating LCMV or with antigen -expressing DCs readily induced a tumorspecific CTL response. 42, 53 Importantly, even the tumor cells themselves induced an immune response in tumor-bearing mice when they reached secondary lymphoid organs. These experiments illustrate that ignorance of peripheral tumors may be one of the main obstacles to an efficient immunosurveillance of solid tumors. They also indicate that early trapping of tumor cells in secondary lymphatic organs is beneficial because it induces CTLs that reject the tiny tumors early. In contrast, late metastasis to lymphoid organs with histologically detectable tumor cells usually indicates a worsening prognosis. 54 The fact that tumor cells are detectable in lymph nodes indicates that they have evaded recognition by the immune system. In addition to the welldocumented mechanisms such as antigen loss, MHC class I down -regulation, and the expression of inhibitory molecules, 11 the formation of an isolating coat that separates naive CTLs from the tumor cells may explain the formation of lymph node metastasis 42 ( Fig 2 ) . In the latter case, naive CTLs do not have contact with the tumor antigen and the tumor in the periphery is ignored by specific CD8 + T cells ( Fig 1B ) .
CTLs respond to antigens that become transiently presented within organized lymphoid tissues for at least 3-5 days. In contrast, T cells do not react against antigens that are continuously present in lymphoid organs. 55, 56 Antigen that is continuously present in secondary lymphoid organs will activate and delete all T cells specific for that antigen. The process of activation followed by physical deletion of the T cells is termed exhaustion. Some noncytopathic persistent infections that are transmitted from mother to offspring or an overwhelming infectious dose of a rapidly replicating virus in adults can lead to this form of tolerance. 56 Lymphohematopoietic tumors develop within organized lymphoid tissues and should, therefore, induce an efficient immune response. That this may indeed be the case is illustrated by the fact that immunosuppression markedly increases the incidence of these tumors. 20 Lymphomas and leukemias that escape immunosurveillance and become clinically evident may use strategies similar to those used by persistent noncytopathic viruses. The injection of a lymphoma cell line expressing LCMV-GP intravenously (i.v.) induced a specific immune response and the transferred lymphoma cells were routinely rejected. However, if a large number of lymphoma cells were injected (>10 7 ), the specific cells were tolerized by exhaustion and the mice died of the lymphoma 42 ( Fig 1D ) . Comparably, studies addressing the role of CD4 + T cells in the control of a murine lymphoma revealed an induction of antigen -specific CD4 + T-cell tolerance early during tumor development. 57 In summary, the discussed experiments reveal the following simple rules that determine immunoreactivity ( Fig 3) : ( a) a low antigen dose in lymphoid organs is not sufficient to induce a CTL response and, as a consequence, antigens that strictly stay outside lymphoid organs are 
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Costimulation
T-cell activation has been shown to require two distinct signals. Supporting evidence compatible with this hypothesis is derived mainly from in vitro studies, but also from some in vivo studies. 58 -63 Signal 1 is delivered by the interaction between the T-cell receptor ( TCR ) and antigenic peptides presented on MHC molecules. The second signal is provided by at least one of several antigen -nonspecific costimulatory signals, 63, 64 including the interaction of CD28 on T cells with B7 family molecules on professional APCs. TCR stimulation without involvement of second signals has been correlated with induction of T-cell anergy or deletion. 58, 60, 63, 64 Additional second signals include members of the TNFR family (CD40 -CD40L, CD27 -CD70, OX40-OX40L, 4 -1BB -4 -1BBL, and others ) 65 -68 as well as soluble molecules such as IL-2, IL -12, and IL -18 69 and molecules involved in cell adhesion and T-cell stimulation such as LFA -1 and ICAM -1. 70 The two -signal hypothesis originally explained contact-dependent cooperation of CD4 + T cells and B cells 58 but was then extended generally to induction of T cells. 59 Although activation of CD8 + T cells may be less dependent on costimulation than activation of CD4 + T cells, expression of costimulatory molecules or cytokines has been shown to variably enhance CTL activation and proliferation, 64, 69 and offers rationales to explain the lack of antitumor immunity as well as new possibilities for enhancement of such CTL responses. 71, 72 It is important and interesting to note that, whereas studies in CD28 À / À or B7 À / À mice have demonstrated that CD28 -B7 interactions enhance T-cell responses in lymphoid organs, the role of such interactions in solid peripheral 
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Tumor immunosurveillance and immunotherapy AF Ochsenbein tissues is largely based on theoretical considerations and on indirect evidence based mainly on experiments with tumors. 61, 62 Experiments performed during the past 10 years have documented that expression of costimulatory signals on tumor cells improves immunogenicity in several murine tumor models as assessed by resistance against primary tumor establishment or more efficient protection against a tumor challenge. 61, 62, 66, 71, 72 Nevertheless, eradication of already established peripheral tumors ( i.e., growing for more than 8 -10 days ) by enhancement of costimulation was hardly ever observed. In contrast to these experimental tumor models that used injections of single cell suspensions, LCMV-GP and B7.1-expressing tumors did not induce a CTL response if they stayed outside of secondary lymphoid organs. 42 Tumor antigen and second signal-expressing tumors transplanted as solid tumor fragment s.c. or injected s.c. into lymph node deficient aly /aly mice did not elicit a specific CTL response and the peripheral tumors were ignored by the immune system. In contrast, CTL priming in lymphatic organs in CD28 À / À mice was reduced by a factor of about 100. 42, 74 One might argue that in vivo, one costimulatory signal expressed alone on a peripheral tumor may not be sufficient to activate naive T cells and several different second signals may be necessary. The experiments with aly / aly mice indicate, however, that both abundance of costimulatory signals including B7.1, B7.2, CD40L, and CD70, 62 -65 and soluble factors such as IL-2 69 are offered only within the anatomic structure of secondary lymphoid organs in a manner necessary and sufficient for interaction of naive CD8 + T cells with antigen-expressing cells in a bystander or a linked manner 75 -probably together with CD4 + T cells -to result in a CTL response.
The question then remains as to what is the contribution of a costimulatory molecule expressed on a peripheral tumor to the overall antitumor immune response. A relatively more efficient rejection of B7 + tumor cells injected as cell suspensions has been demonstrated in various studies previously. 61, 62, 72 Adoptive transfer experiments revealed that, although LCMV-GP and B7.1-expressing solid tumors did not induce specific CTL outside of secondary lymphoid organs, the expression of a second signal on the tumor enhanced / maintained already primed CTL responses. 42 This is compatible with reports on the role of B7 in the effector phase of a CTL response in a peripheral tumor 76, 77 and may well extend also to experimental autoimmune encephalitis 78 and to results on enhanced diabetes in transgenic mice expressing a specific CTL target peptide and B7 in islet cells. 79 Taken together, many observations indicate that tumors expressing costimulatory molecules are usually rejected more efficiently than control tumors. 62, 72, 75, 77 However, most analyses did not rigorously distinguish induction from enhanced maintenance of effector T cells. Costimulatory signals expressed within secondary lymphoid organs shift the dose -response curve for the induction of naive CTL to lower antigen doses, but a single costimulatory signal expressed on a peripheral tumor is not sufficient to activate naive CTL. Additional expression of costimulatory signals on tumor cells seems not to increase their immunogenicity within secondary lymphoid organs. However, a key role of costimulatory signals on peripheral tumors may be to enhance / maintain already primed T-cell responses against the tumor. 42, 73, 76, 77 This peripherally enhanced /maintained immune response in tumors expressing costimulatory molecules is apparently able to more efficiently control the tumors at an early stage.
Cross -priming by professional APCs
Two pathways of antigen presentation have been described in vivo. Exogenous antigens are taken up by professional APC (pAPC) including DCs, B cells, and macrophages. They are then processed, loaded on MHC class II molecules, and presented to specific CD4 + T cells. Cytoplasmatic proteins or foreign proteins that are produced in the cytoplasm, i.e., viral proteins, reach the endoplasmatic reticulum by a TAP -dependent mechanism. In the RER, they are loaded on MHC class I and presented as 8 -to 10 -aa -long peptides to CD8 + T cells. Cancer Gene Therapy In vitro experiments clearly indicated that DCs process exogenous cell debris and present the peptides on MHC class I. This process may be even more efficient for apoptotic cells than for necrotic cells. 82 The molecular mechanisms of this process have been analyzed in detail. These include regurgitation of peptides produced in the endocytic pathway and exogenous loading on MHC class I, antigen in phagolysosomes gaining access to the cytosol by the chaperoning of heat shock proteins ( HSPs ), and direct entry to the cytosol by macropinocytosis. 86 However, high antigen doses have to be used to reach MHC class I presentation in vitro.
82,87 -89
Antigen presentation on MHC class II is achieved more easily and with lower antigen doses. The question, therefore, remains if cross -priming is also of relevance in vivo and if conditions similar to the in vitro experiments are reached in vivo.
In vivo, cross -presentation has been analyzed with minor histocompatibility differences. It was shown that minor histocompatibility antigens, together with H -2 b on cells, injected into F1 (bxd ) mice prime CTLs that are H -2 d -restricted. 80, 90, 91 But in none of these cases has it been shown that a protein or gene product within the H -2 b cell actually was processed and reexpressed through class I on the F1 cell in association with H -2 d . What happens in these minor histocompatible antigen situations is, therefore, unclear at the molecular level. Cross -presentation has been claimed to be responsible for tolerance and activation in experimental systems showing that APC and CTL do necessarily have to express the same H -2 restriction for activation of CTLs. 92 However, the interpretation drawn from those experiments that MHC class I-restricted antigens are presented by pAPC is not necessarily correct. pAPCs have to present MHC class II -restricted antigens to CD4 + T cells to provide help. 93 If this pathway is blocked (by CD4 + T-cell depletion or by producing chimeras with allogeneic bone marrow ), CD8 + T-cell priming is no longer possible. In addition, experiments showing cross -priming in OVAtransgenic mice were usually done with TCR -transgenic T cells. 94 The , and P815 (mastocytoma, H -2 d ) tumor cells. 42 The resulting CTL response was, in all cases, limited to the haplotype of the immunizing cells, indicating that the efficiency and physiological relevance of cross -priming in vivo are very low or absent. In addition, in an allogeneic bone marrow transplantation model, Shlomchik et al 95 showed that despite the presence of numerous donor APCs, only host -derived APCs presented minor histocompatibility antigens in vivo and initiated graft -versus -host disease. Thus, cross -priming of recipient minor histocompatibility antigens on donor APC was inefficient.
Taken together, cross -presentation may be induced in vitro to load APC with exogenous proteins and may be observed also in vivo in TCR -transgenic systems but is very inefficient when analyzed on a peptide level in a nontransgenic situation, indicating that cross -presentation in vivo is not impossible but rather the exception than the rule. The lack of relevant cross -priming may explain why most peripheral solid tumors do not induce an efficient antitumor immune response.
Implications for immunotherapy of tumors
Understanding the reasons why tumors usually do not induce an efficient CTL response is a key to designing more efficient CTL -based vaccine strategies. 96, 97 A crucial step in the diagnostic process before initiating immunotherapy is to determine whether immunosurveillance failed because of immunological ignorance or because of a form of immunological tolerance including the deletion of the specific T cells. In the first situation, specific CTLs are present in secondary lymphoid organs and can be activated by an active immunization protocol, as discussed below. If, however, immunosurveillance fails because of exhaustion of the specific CTL, an active immunization strategy obviously will be inefficient and the adoptive transfer of ex vivo activated and expanded T cells may be a promising approach. 98 The overall rejection success depends on the relative kinetics of tumor cell numbers (or tumor size, influenced by growth rate and several other tumor parameters ) versus kinetics and relative numbers of effector T cells over time. An initial maximal reduction of the tumor or leukemia load by chemotherapy or surgery is, therefore, crucial for the success of an immunization protocol.
Providing antigen to secondary lymphoid organs
Various strategies and carriers have been used to provide antigen to the patients' immune system as a vaccine. 96 DCs are assigned a central role in the presentation of the antigen with most vaccination strategies. One possibility that has already been tested extensively in clinical phases I and II trials is the injection of DCs that are loaded in vitro with the specific tumor antigen or peptide. 99 DCs migrate through the
Cancer Gene Therapy
Tumor immunosurveillance and immunotherapy AF Ochsenbein afferent lymph to secondary lymphoid organs and present the antigen to specific CTL. Similarly, the injection of peptide s.c. or intradermally ( i.d. ) 100 -102 or the immunization with DNA 103 will result in the presentation of antigen by host APC. It is interesting to note that most of these immunization protocols are more efficient if the antigen is directly injected into lymphoid organs. 104 A factor of 100-1000Â less peptide or recombinant DNA is necessary to induce an immune response when directly injected into lymphoid organs. However, a limitation of all these immunization strategies is the difficulty in maintaining a highenough antigen concentration in lymphoid organs over a sufficient time period. Strategies to overcome this problem include prime -boost protocols that vary from immunizations once every week to once every 3 months. 105, 106 What then are the requirements that a possible therapeutic vaccine against an established tumor has to fulfill? Experiments using DC that constitutively express the LCMV-GP33 for immunization protocols against tumors 53, 107 but also for the induction of diabetes in the RIP -GP model 50 highlighted the importance of a continuous presence of antigen within lymphoid organs for at least 7-14 days. Repetitive exposure to antigen within this early time period increased the frequency of specific CTLs whereas booster immunizations after this first expansion did not further increase CTLp frequency (Fig 4A -D ) . However, repetitive booster injections of antigen -expressing DC kept specific CTL activated with the ability to lyse target cells ex vivo. In a murine model with established LCMV-GP -expressing tumors, mice were immunized once with 200 plaque -forming units ( pfu ) of LCMV-WE i.v. or 10 5 LCMV-GP33 -41 -expressing DCs or with 2Â10 6 single MC -GP tumor cells injected s.c. that reach draining lymph nodes and spleen. By these immunizations of short duration ( < 7 days), tumor growth was retarded only negligibly ( Fig 4E ) . A comparable minimal effect of a single vaccination had been shown in the case of a LCMV-GP -positive insulinoma. 108 If, however, mice were immunized either with a high dose of 2Â10 6 pfu of LCMV-WE causing a prolonged and widely spreading infection with long -term CTL activation, or alternatively by repeated injections of LCMV-GP -expressing DC or MC -GP in 2 -to 5 -day intervals for 3 weeks, most tumor fragments failed to grow further and eventually disappeared completely ( Fig 4F ) . Thus, an antigen -driven prolonged CTL response is needed to reject peripheral tumors, initially for maximal expansion of the CTLp frequency and later to maintain the specific CTLs activated and able to lyse target cells.
Providing costimulatory signals
The two-signal hypothesis has led to experimental immunization protocols providing additional costimulatory signals. 62, 66, 71, 72 Solid tumors usually do not express costimulatory signals. Transfection of carcinoma and sarcoma cells with B7 or other costimulatory molecules resulted in greater immunogenicity and tumor cells expressing second signals were usually rejected more efficiently. 61 Similarly, genes that encode B7 molecules were included into recombinant DNA and viral vectors for antigen -specific vaccination. 109 As outlined above, these additional costimulatory signals may not necessarily improve the initial priming of a T cell within lymphoid organs but instead maintain or even expand antigen -experienced CTL in the periphery. Another way to augment a specific immune response is to provide antibodies specific for a costimulatory molecule that mediates mitogenic signals for T-cell activation and growth. 73, 110 In murine tumor models, the administration of anti -4-1BB mAb led to the impressive regression of established poorly immunogenic sarcomas and highly tumorigenic mastocytomas. 73 Because primed but not naive 
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Tumor immunosurveillance and immunotherapy AF Ochsenbein T cells express 4-1BB, it is most likely that the administration of the antibody augmented an undetectable but weak antitumor response by maintaining /amplifying primed T cells in the periphery. In addition, recent evidence indicates that stimulating antibodies specific for some costimulatory molecules might even be able to break anergic tolerance. 111 Therefore, promising approaches include strategies enhancing costimulation by directly transfecting tumor cells in peripheral tumors in vivo with virus vectors encoding a second signal or by providing costimulatory antibodies. However, it is important to emphasize that although improving costimulation will shift the dose -response curve for the induction of specific CTL to lower antigen doses, it will not overcome the requirement that the tumor antigen has to be present in lymphoid organs for the induction of the specific immune response.
Improving the efficiency of cross -priming
The lack of relevant cross -priming explains why peripheral antigens on tumors or on b-cells of the pancreatic islet are ignored by the immune system. 42, 44, 45 However, developing strategies to enhance cross -priming of tumor antigens would be very attractive for vaccination protocols in order to overcome the problem that restricting epitopes have to be characterized for each MHC molecule. One strategy to improve the uptake of exogenous antigens and its processing and presentation on MHC class I is to incubate DCs with large amounts of antigen in vitro ( i.e., concentrations that would never be reached under physiological conditions in vivo ). 82,87 -89 It seems sufficient to introduce the antigen to the cytosol to reach peptide processing and a TAP -dependent presentation on MHC class I. Therefore, in vitro electroporation 112 or fusiogenic liposomes 113 allow the entry of exogenous material to the MHC class I pathway of antigen presentation. Liposomes containing the tumor antigen may also be used for in vivo priming of CTLs, especially if the access to the cytosol is increased by the addition of lysteriolysin O to the liposomes, which allows the lysis of the phagolysosome and the entry of the tumor antigen into the cytosol. 114 In contrast, more recent evidence suggests that receptor-mediated endocytosis is more efficient and requires lower amounts of antigen. Antigens from apoptotic bodies, 82 complexed to IgG 31 or coupled to HSPs, 115, 116 are endocytosed through scavenger, Fcg, or HSP receptors, respectively, and cross -presented by DCs to CTLs. These mechanisms may be employed to load exogenous antigen on MHC class I molecules in vitro and potentially also in vivo. Recently, Jeannin et al. 117 showed that whole antigen coupled to a Klebsiella pneumoniae protein (kpOmpA ) specifically bound to a receptor on professional APCs and resulted in the delivery of antigen into the MHC class I presentation pathway. Simultaneous immunization with kpOmpA coupled to ovalbumin resulted in protection against a tumor challenge with ovalbumin -expressing tumor cells.
Viral vectors for the induction of antitumor immunity
Considering the reasons why the endogenous immune response fails to protect against tumors, recombinant viruses seem an ideal candidate to immunize against tumors. Viruses often infect and replicate within professional APCs and they reach high titers in secondary lymphoid organs. By infecting pAPC, they overcome the problem of inefficient crosspriming, their antigens are presented by pAPC in the context of costimulatory molecules, and the infected pAPC migrates to local lymph nodes. Therefore, there is wide interest in the use of vaccines composed of attenuated viruses or bacteria as carriers of tumor antigens. 118 -120 More than 20 different RNA and DNA viruses as well as bacteria are used as vectors including poxviruses (especially the highly attenuated strain Ankara, as well as fowlpox and canarypox ) but also adenoviruses and herpesviruses. 121 Each of these vectors has various advantages and disadvantages and currently no viral vector can clearly be favored over the others. These attenuated viruses usually infect human cells but do not replicate or do so only to a very limited extent in vivo. Attenuation of these viruses is necessary to prevent disease induction in the immunized patient and potentially to prevent horizontal spread of the recombinant virus. However, attenuation also limits their use as vaccine carriers because their short in vivo persistence and limited production of tumor antigen prevent them from inducing and sustaining antitumor CTL responses. In addition, after the initial immunization, a cell -and antibody -based immune response against the viral carrier is elicited, which limits the possibility of booster immunization with the same recombinant virus. This limitation has led to the concept of cycling different viral vectors in prime -boost protocols. 106 Indeed, a marked enhancement of immunization potency has been observed with prime-boost protocols using different recombinant viruses, e.g., fowlpox followed by vaccinia virus. 122 Taken together, an ideal viral vector for tumor immunotherapy should combine prolonged persistence and replication in vivo with minimal risk for disease induction in the patient and horizontal spread -a goal that is difficult to reach.
Conclusion
Understanding why the endogenous immune response fails to control tumorigenesis is key to improving antitumor immunity. The antigen dose localization concept for the induction of CTLs proposes that the immunosurveillance of peripheral tumors fails because of immunological ignorance, whereas lymphohematopoietic tumors may induce tolerance to evade immune recognition. In the situation of immunological ignorance of a tumor, a vaccine efficiently delivering tumor antigen to secondary lymphoid organs may lead to tumor control and eradication if the tumor load is neither too great nor too difficult to reach. Only continued stimulation of either endogenous host or in vitro expanded and adoptively transferred effector T cells will likely be sufficient to lead to rejection of tumors quickly enough before the selection of escape mutants. Alternatively, in a situation where a widely spreading tumor induces tolerance, high -avidity T cells may not be available due to either anergy or deletion. These concepts are being evaluated in both animal models and clinical trials in order to better understand tumor immunity. It is hoped that such information, along with other recent advances in understanding tumor immunosurveillance, will make it possible to develop more specific and novel therapeutic approaches to treat cancer.
